Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-06-05 17:02:57 ET · period of report 2026-06-05 · accession 0002020969-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-05 17:02 | 2026-06-05 | RXRX | Khan Najat | CEO, Pres, Dir | S - Sale | $3.58 | -23.6K | 2.18M | -1% | -$84.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-06-05 | S | D | 23,588 | $3.58 | 2,175,796 | D | — | — | (F1) This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $3.56 to $3.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |